Endocrine Abstracts

Previous studies have shown that Rituximab (RTX) is effective as a disease modifying drug at doses of 500 mg or 1000×2 mg in active Graves’ orbitopathy (GO). We have conducted a pilot study (EUDRACT 2012-001980-53) in which patients with active moderate-severe GO were treated with a single infusion of low dose RTX (100 mg). Ten patients were enrolled of whom seven completed the study at 52 weeks. Five patients did not respond to a previous treatment with i.v. methylp...

Objectives: Dysthyroid Optic Neuropathy (DON) is a severe complication of Graves’ Orbitopathy (GO), requiring prompt treatment. First line treatment is high dose intravenous steroids, then surgery is considered mandatory. We studied the clinical outcomes of surgery for DON, with and without previous therapy with steroids.Methods: 88 orbits of 56 patients with DON were treated with surgical orbital decompression. 33 orbits (37.5 %) underwent surgery ...